touchLearning Activities
In this interview, Dr Elena Crisà (Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy) shares her insights into the most fulfilling aspects of practicing haematology, from working in cutting-edge new treatment options in clinical trials to guiding patients through complex treatment decisions.
Protagonist Therapeutics Inc. and Takeda have shared positive topline findings from the phase III VERIFY trial (NCT05210790), which investigated rusfertide in patients with polycythemia vera (PV) who require frequent phlebotomies. Participants were randomly assigned to receive either rusfertide or a ...
"Our job is to empower patients with data to make the most informed decision, together" For Dr. Carmelo Gurnari (Cleveland Clinic, Cleveland, OH, USA; University of Tor Vergata, Rome, Italy), haematological oncology is more than a profession – it is a ...
Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and ...
CD7-targeted CAR T-cell therapy, WU-CART-007, demonstrates encouraging anti-leukemic activity and a manageable safety profile in heavily pretreated patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). This updated analysis from the phase II portion ...
A chemotherapy-free approach combining ibrutinib-rituximab (IR) has outperformed standard chemotherapy regimens in treating older patients with newly-diagnosed mantle cell lymphoma (MCL), according to findings from the ENRICH trial presented at the 66th American Society of Hematology Annual Meeting. The study ...
The American Society of Hematology (ASH) held its 66th Annual Meeting from 7–10 December 2024. Among the highlights of the meeting were six late-breaking abstracts that have the potential to influence how healthcare professionals approach a range of condition,s from introducing ...
With the the 66th ASH Annual Meeting & Exposition still fresh in our minds, Dr Rahul Banerjee (Fred Hutch Cancer Center, Seattle, WA, USA) and Dr Samer Al Hadidi (University of Arkansas for Medical Sciences, Little Rock, AR, USA) outline ...
The IMpactMF trial is a phase 1/1b study evaluating the addition of Imetelstat to ruxolitinib for myelofibrosis patients who show an inadequate response to ruxolitinib alone. By combining these therapies earlier in treatment, the study aims to assess safety, tolerability ...
As 2024 draws to a close, we’re celebrating a great year of content. From insightful expert Q&As and news articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the haematology community with high-quality, easily accessible content.
The 66th ASH Annual Meeting and Exposition 2024 in San Diego saw approximately 30,000 visitors, 8,000 abstracts and 275 exhibitors. With so much exciting new data and scientific breakthroughs presented, touchHAEMATOLOGY is excited to break this down and bring you some of the highlights. ...
This interview features Dr Nico Gagelmann (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) and Dr Claire Horgan (Royal Manchester Children's Hospital, Manchester, UK) co-chairs of the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee. Together, they discuss their motivations ...
The 66th ASH Annual Meeting and Exposition is now just one week away! From December 7-10th 2024, San Diego, California is set to welcome over 30,000 health professionals, clinicians, researchers, educators and over 275 exhibitors, both in person and online, from around ...
Prof. Pierre Fenaux, Head of the Department of Hematology and Immunology at Assistance Publique-Hôpitaux de Paris Nord (Hôpitaux Saint-Louis, R Debré, Avicenne) is a leading expert in haematology with extensive experience in the treatment and management of myelodysplastic syndromes (MDS). In this interview, he discusses key considerations for first-line therapies in lower-risk MDS, the latest advances in treatment and the role of organizations like the European School of Hematology (ESH) in supporting haematologists.
In this interview, Prof. Robin Foà, a distinguished haematologist and now Emeritus Professor of Haematology at the Sapienza University of Rome, Italy, shares the inspirations and career-defining moments that led him to focus on haematology and leukaemia research. Initially trained ...
Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.
In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
touchHAEMATOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
